Castle Biosciences, Inc. (NASDAQ:CSTL) Director Daniel Bradbury Sells 7,867 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) Director Daniel Bradbury sold 7,867 shares of the firm's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $29.14, for a total value of $229,244.38. Following the sale, the director now directly owns 1,425 shares in the company, valued at $41,524.50. This trade represents a 84.66 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Castle Biosciences Stock Performance

Shares of NASDAQ CSTL traded up $0.55 during midday trading on Wednesday, reaching $32.72. 351,560 shares of the company were exchanged, compared to its average volume of 334,492. The stock has a market cap of $916.39 million, a P/E ratio of 163.61 and a beta of 0.92. Castle Biosciences, Inc. has a 1 year low of $16.97 and a 1 year high of $35.84. The stock has a fifty day simple moving average of $29.95 and a 200 day simple moving average of $27.74. The company has a current ratio of 7.78, a quick ratio of 7.64 and a debt-to-equity ratio of 0.02.

Castle Biosciences (NASDAQ:CSTL - Get Free Report) last announced its earnings results on Monday, November 4th. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.14. Castle Biosciences had a return on equity of 1.47% and a net margin of 1.95%. The company had revenue of $85.78 million for the quarter, compared to the consensus estimate of $78.55 million. During the same period last year, the business posted ($0.26) EPS. On average, research analysts forecast that Castle Biosciences, Inc. will post 0.34 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Castle Biosciences

Institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its holdings in shares of Castle Biosciences by 165.2% in the third quarter. JPMorgan Chase & Co. now owns 69,409 shares of the company's stock valued at $1,980,000 after acquiring an additional 43,241 shares in the last quarter. Principal Financial Group Inc. lifted its position in Castle Biosciences by 2.7% in the third quarter. Principal Financial Group Inc. now owns 1,538,520 shares of the company's stock valued at $43,879,000 after purchasing an additional 40,377 shares during the period. Franklin Resources Inc. boosted its holdings in Castle Biosciences by 87.3% in the 3rd quarter. Franklin Resources Inc. now owns 69,382 shares of the company's stock valued at $1,979,000 after purchasing an additional 32,344 shares in the last quarter. Barclays PLC increased its position in Castle Biosciences by 310.7% during the 3rd quarter. Barclays PLC now owns 52,301 shares of the company's stock worth $1,491,000 after purchasing an additional 39,567 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Castle Biosciences by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 624,683 shares of the company's stock worth $17,820,000 after buying an additional 7,004 shares in the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on CSTL shares. Robert W. Baird raised their price objective on shares of Castle Biosciences from $37.00 to $39.00 and gave the stock an "outperform" rating in a report on Tuesday, November 5th. KeyCorp lifted their price target on shares of Castle Biosciences from $28.00 to $36.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 5th. Scotiabank upped their price objective on shares of Castle Biosciences from $37.00 to $44.00 and gave the company a "sector outperform" rating in a research note on Wednesday, November 6th. Lake Street Capital lifted their target price on Castle Biosciences from $34.00 to $40.00 and gave the stock a "buy" rating in a research report on Tuesday, November 5th. Finally, BTIG Research upped their target price on Castle Biosciences from $35.00 to $40.00 and gave the company a "buy" rating in a research report on Monday, October 14th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $40.29.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.